Avoro Capital Advisors LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001633313

What is a 13F filing? Who files one and when · What 13F filings can't tell you

LargeFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 26 positions · Total reported value $11.14B · Top-10 concentration 79.5% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 62.1% · 3 new · 15 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -15.9% · vs SPY -18.0% · Prev Value $11.14B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -0.4% · vs SPY -2.6% · Latest Value $9.67B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, Avoro Capital Advisors LLC disclosed 26 equity positions with a combined reported value of $11.14B. The filing implies a focused portfolio: its ten largest positions account for 79.5% of reported value. HoldingsHub classifies the profile as Large / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were UTHR ($1.51B), ASND ($1.36B), KRYS ($1.07B). By sector, the heaviest allocations are Health Care 99.7%, Other 0.3%. Versus the prior quarter, allocation shifted toward Health Care (+15.8pp) and away from Other (-15.8pp).

Versus the prior quarter, Avoro Capital Advisors LLC opened 3 new positions, trimmed 15 and fully exited 0, a turnover rate of 62.1% of positions. The portfolio's overlap with the prior quarter was 75% of names.

The largest new positions opened in Q2 2026 were COAG ($70.71M), FTH ($36.10M).

Of the 6 positions fully exited versus the prior quarter, the largest were APLS ($491.70M), CNTA ($454.02M), TERN ($300.24M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • COAG HEMAB THERAPEUTICS HLDGS INC · $70.71M
  • FTH FAETH THERAPEUTICS INC · $36.10M

Fully Exited (vs previous quarter)

  • APLS APELLIS PH · prev qtr: $491.70M
  • CNTA CENTESSA PHARMACEUTICALS PLC · prev qtr: $454.02M
  • TERN TERNS PHARMACEUTICALS INC · prev qtr: $300.24M
  • SLNO SOLENO THERAPEUTICS INC · prev qtr: $77.00M
  • ALKS ALKERMES PLC · prev qtr: $42.43M
  • MNKD MANNKIND CORP · prev qtr: $5.39M

Insider Transactions (Form 4)

Latest Avoro Capital Advisors LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-07-28 Buy Scribe Therapeutics, Inc. 7,905 $18.25 SEC filing
2026-07-24 Buy Scribe Therapeutics, Inc. 50,000 $22.31 SEC filing
2026-07-24 Buy Scribe Therapeutics, Inc. 2,333,333 $15.00 SEC filing

All insider transactions →

Fund Profile

Avoro Capital Advisors LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 26 US equity positions with a combined value of $11.14B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-74391 (status: Approved), registered 2012-03-30
  • Regulatory AUM (Form ADV): $13.55B as of 2026-03-05
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 1 hedge funds
  • Website: avorocapital.com

Portfolio Structure

  • 26 positions · $11.14B reported value (Q2 2026)
  • Top 10 holdings = 79.5% of reported value
  • Largest position: UTHR (UNITED THERAPEUTICS CORP DEL) at 13.5%
  • Average position size: $428.32M

Sector Tilt

  • Health Care 99.7%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 2 new, 12 added, 3 reduced, 6 exited
  • 9 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Avoro Capital Advisors LLC appears to be maintaining a bullish stance on the healthcare sector, with a significant increase in positions in biotechnology and pharmaceutical companies. This suggests a belief in the long-term growth potential of these sectors. 2. Key Moves: - Added: United Therapeutics Corp (UTHR) and Ascendis Pharma A/S (ASND) were added to the portfolio, with substantial increases in share count. Arrowhead Pharmaceuticals Inc (ARWR) and Celularity Inc (CYTK) were also added, with ARWR seeing a notable increase in share count. - Reduced: Revolution Medicines Inc (RVMD) was reduced in the portfolio. - Hold: No significant changes were made to the positions in Krystal Biotech Inc (KRYS), Madrigal Pharmaceuticals Inc (MDGL), Argenx SE (ARGX), Arrowhead Pharmaceuticals Inc (ARWR), Kymera Therapeutics Inc (KYMR), and Cellectis Inc (CELC). 3. Portfolio Structure: - Passive/Active: The portfolio seems to be active, as there are significant additions and reductions in positions. - Sector Bias: The fund has a strong bias towards the healthcare sector, particularly biotechnology and pharmaceuticals. - Risk Appetite: The risk appetite is moderate, with a focus on growth-oriented companies in the healthcare sector. 4. Per-Holding One-Liner: - UTHR: United Therapeutics Corp is a biotechnology company focused on developing therapies for respiratory and cardiovascular diseases. - ASND: Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapies for rare genetic disorders. - KRYS: Krystal Biotech Inc is a biopharmaceutical company focused on developing therapies for dermatological and orphan diseases. - MDGL: Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on developing therapies for metabolic diseases. - ARGX: Argenx SE is a biopharmaceutical company focused on developing therapies for cancer and rare diseases. - ARWR: Arrowhead Pharmaceuticals Inc is a biopharmaceutical company focused on developing RNA interference therapeutics. - KYMR: Kymera Therapeutics Inc is a biopharmaceutical company focused on developing therapies for genetic diseases. - RVMD: Revolution Medicines Inc is a biopharmaceutical company focused on developing therapies for cancer and other diseases. - CYTK: Cytokinetics Inc is a biopharmaceutical company focused on developing therapies for cancer and other diseases. - CELC: Cellectis Inc is a biopharmaceutical company focused on developing therapies for genetic diseases. 5. One-Sentence Style Summary: Avoro Capital Advisors LLC's rebalancing in Q2 2026 reflects a strategic bet on the healthcare sector, particularly biotechnology and pharmaceuticals, with a focus on growth-oriented companies and active management.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 99.7%
Other 0.3%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 2.78M $1.51B 13.52%
13.52%
Add
2 5.11M $1.36B 12.24%
12.24%
Add
3 2.89M $1.07B 9.64%
9.64%
Hold
4 1.83M $984.41M 8.84%
8.84%
Add
5 1.00M $927.77M 8.33%
8.33%
Hold
6 11.36M $925.59M 8.31%
8.31%
Add
7 7.47M $857.13M 7.70%
7.70%
Hold
8 2.30M $430.18M 3.86%
3.86%
Reduce
9 5.00M $425.95M 3.83%
3.83%
Add
10 3.40M $355.71M 3.19%
3.19%
Add
11 6.56M $351.84M 3.16%
3.16%
Hold
12 5.78M $348.75M 3.13%
3.13%
Hold
13 7.19M $338.17M 3.04%
3.04%
Add
14 6.73M $309.88M 2.78%
2.78%
Add
15 5.72M $245.61M 2.21%
2.21%
Reduce
16 23.89M $162.68M 1.46%
1.46%
Add
17 12.54M $123.14M 1.11%
1.11%
Add
18 3.78M $98.40M 0.88%
0.88%
Hold
19 1.93M $70.71M 0.64%
0.64%
New
20 1.80M $48.38M 0.43%
0.43%
Hold
21 2.50M $45.92M 0.41%
0.41%
Add
22 1.34M $44.79M 0.40%
0.40%
Hold
23 2.33M $43.12M 0.39%
0.39%
Add
24 1.44M $36.10M 0.32%
0.32%
New
25 2.85M $13.05M 0.12%
0.12%
Hold
26 1.49M $6.93M 0.06%
0.06%
Reduce

FAQ

What did Avoro Capital Advisors LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, Avoro Capital Advisors LLC reported 26 equity positions worth $11.14B in aggregate; its largest disclosed positions were UTHR ($1.51B), ASND ($1.36B), KRYS ($1.07B).

How large is Avoro Capital Advisors LLC's portfolio?

Avoro Capital Advisors LLC reported $11.14B of long equity holdings across 26 positions as of 2026-Q2. Top-10 holdings account for 79.5% of reported value.

What is Avoro Capital Advisors LLC's investment style?

HoldingsHub classifies the portfolio as Large / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/avoro-capital-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →